الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 255 |  |  |
| | | from | 255 | | |
Abstract
Endometrial cancer (EC) identified at an early stage is successfully treated in a majority of patients with surgery with or without radiotherapy or chemotherapy. For patients with advanced disease, however, the prognosis is poor; 5-year survival rates are less than 50% in patients with lymph node metastases and less than 20% in those with peritoneal or distant metastases (Herzog,2015). Previous studies proved that PD1-/PD-L1 blockers are currently effectively used as immunotherapies in a number of tumors such as melanoma and non-small cell lung cancer. This study is conducted to determine the expression of PD-L1 in endometrial carcinoma and to assess its potential role as a biomarker for different types that can be used to screen candidates fit for immunotherapy. (Gasparri,et al.,2017)